GENE ONLINE|News &
Antibody Drug Conjugates: The Next Big Thing in Cancer Therapy?
Cancer is the second most common cause of global deaths, accounting for approximately 10 million per year. It is estimated that in 2021 there will be an additional 1.9 million new cases in the US alone, with around 600,000 deaths. Cancer therapy has improved over the last decade, thanks to technological advances and research Progress. Here we take a closer look at one such significant advance, the antibody conjugated drugs (ADCs).
What are ADCs?
GO Prime with only $1.49 now
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
